Hims & Hers Health Inc. was modestly higher in pre-market trading, up 0.2% and hovering around $31.54, as market participants parsed a recent analyst note that highlighted potential regulatory upside from a July advisory committee session.
Leerink Partners analyst Michael Cherny reiterated a Market Perform rating and kept a $25 price target on the stock, while mapping out how a favorable outcome at the Pharmacy Compounding Advisory Committee meeting on July 23-24 could open a new revenue avenue for the telehealth platform beginning in fiscal 2027.
The crux of Cherny's analysis is the upcoming PCAC meeting, where regulators will consider whether seven specific peptides should be added to the FDA's 503A Bulk List. Inclusion on that list would allow licensed drug compounders, such as Hims & Hers, to manufacture those peptides. Cherny described the meeting as a "modest binary event" - a single regulatory decision that could produce material upside if the committee issues a positive recommendation.
At the same time, Cherny signaled caution. He pointed out that historical PCAC voting patterns have produced mixed results and emphasized that the FDA does not always adhere to the committee's suggestions. That caveat keeps the outcome uncertain even if the committee recommends adding the peptides to the list.
Adding a small near-term investor concern, a Form 144 filing dated June 16 indicated that an insider may be preparing to sell restricted shares, creating a modest overhang on sentiment.
Market context and valuation dynamics
The broader market backdrop was mixed during the pre-open session. The S&P 500 was trading lower by roughly 0.6%, while the Nasdaq Composite was off about 1.2%. The Dow Jones Industrial Average was up about 0.6%, signaling some rotation into more defensive areas of the market. Against that environment, Hims & Hers' ability to maintain pre-market gains attracted attention, although the stock remains far below its 52-week high of $70.43 and is recovering from a 52-week low of $13.74 hit in February.
Cherny and other market participants have treated the stock more like a play on regulatory optionality than as one driven by immediate earnings momentum. Hims & Hers reported an adjusted loss for the first quarter of fiscal 2026 and has provided guidance for full-year revenue in a range of $2.8 billion to $3.0 billion. With the next quarterly report not due until August 10, the July PCAC meeting has emerged as the primary near-term event around which speculative interest is concentrated.
Leerink's neutral rating and a price target below the current trading level serve to temper outright enthusiasm, even as potential approval of the peptides could create a new manufacturing opportunity for the company down the road.
What investors are watching
- The PCAC meeting on July 23-24 regarding the possible addition of seven peptides to the FDA's 503A Bulk List and whether that results in a favorable committee recommendation.
- Any subsequent regulatory actions by the FDA, noting that the agency does not always follow PCAC recommendations.
- Company updates leading into the August 10 earnings report and the potential impact of insider share sales disclosed in the Form 144 filing.